



PUBLIC/PDR

24-04206-05m0  
030-10801

March 7, 1997

Mallinckrodt Medical, Inc.  
2703 Wagner Place  
Maryland Heights, MO 63043  
Telephone (314) 770-7800

Ms. Cassandra Frazier  
Nuclear Materials Licensing Section  
U.S. Nuclear Regulatory Commission  
Region III  
801 Warrenville Road  
Lisle, Illinois 60532-4351


**RE: NRC Question Related to the Pending Second  
License Amendment for the Distribution of 9.7  
Curie (Ci) to 15.4 Ci Ultra-TechnaKow, Dry Top  
Eluting (DTE) Mo-99/Tc-99m Generators.**

Dear Ms. Frazier:

Earlier today we had a telephone discussion regarding the correspondence between Mallinckrodt and the Food and Drug Administration (FDA) regarding 19 Ci size DTE generators. You noted that the New Drug Application (NDA) supplement in the March 5, 1997 response, regarding Mallinckrodt's application for a NRC amendment to distribute larger size generators, referenced a supplement number of "S-013" and that the FDA approvable letter which Mallinckrodt sent to you in an August 14, 1997 response referenced a supplement number of "S-012". We agreed that to resolve this issue, I would need to provide clarification regarding the identity of the two different supplements and also provide a correspondence from Mallinckrodt to the FDA which referenced both the S-012 supplement and larger size generators. The issue regarding the different supplement numbers was discussed with Mr. Ron Bartnick, Manager of Quality/Regulatory Compliance. He stated that the S-012 NDA supplement was for the manufacture and distribution of DTE generators and the S-013 was a supplement to utilize Mo-99 from an additional vendor.

Enclosed as Attachment I, for your review, are portions of the July 1992, Mallinckrodt supplement S-012 for NDA 17-243. In the attachment you will see that S-012 is referenced in the cover letter and the larger size DTE generators, 25 Ci, is referenced in the protocol tests and the test data table. Please also note that the "DTE" generator was previously nicknamed the "Hybrid Generator".

9704170214 970307  
PDR ADDCK 03010801  
C PDR



RECEIVED

MAR 12 1997


REGION III 1997

ml  
31  
DH

We believe that these documents satisfy the issues which you and I discussed earlier today.

Please contact me at (314) 770-7981 if you have any additional questions or if I may be of assistance in any other way.

Sincerely,

A handwritten signature in cursive script, appearing to read "Daniel Riemer", with a long horizontal flourish extending to the right.

Daniel Riemer  
Radiation Safety Officer  
Mallinckrodt, Inc.  
Maryland Heights Facility

Attachment



Attachment I  
1 of 6

July 31, 1992

Mallinckrodt Medical, Inc.  
675 McDonnell Boulevard  
PO Box 5840  
St. Louis, MO 63114  
Telephone 314 893 2000

Food and Drug Administration  
Center for Drug Evaluation & Research  
Office of Drug Evaluation I  
Division of Medical Imaging, Surgical  
and Dental Drug Products, HFD #160  
ATTN: Document Control Room 18B-03  
5600 Fishers Lane  
Rockville, Maryland 20857

RE: NDA 17-243  
Ultra-TechneKow<sup>(R)</sup> FM  
Supplement S-012

Dear Sir/Madam:

Please refer to Mallinckrodt Medical's approved NDA 17-243 for  
Ultra-TechneKow FM (Technetium Tc 99m Generator).

On November 15, 1990, representatives from Mallinckrodt Medical met with  
FDA officials to review a program for modifying our present generator. At  
the meeting it was understood that FDA would require an NDA supplement that  
would include a full description of the generator, methods of manufacture  
and control, stability data, and revised labeling.

On July 1, 1991 Mallinckrodt Medical sent to FDA a draft stability protocol  
for the modified (Hybrid) generator. Based on FDA comments received on  
July 31, 1991, we revised the stability protocol.

Mallinckrodt Medical, hereby, supplements NDA 17-243 with information that  
provides for the manufacture and distribution of the modified generator.

Sincerely,

Robert S. Lake  
Sr. Regulatory Affairs Associate

cc: S. Lange

Ultra-TechneKow<sup>(R)</sup> FM  
(Technetium Tc 99m Generator)NDA 17-243  
SupplementTABLE OF CONTENTS

<u>Item</u>	<u>Page Number</u>
I. Summary of the Supplement	1.001
II. Chemistry, Manufacturing, and Controls	1.004
A. Description of the Generator	1.004
B. Specifications and Test Methods	1.009
1. Reagents	1.009
2. Generator Components	1.010
a. Fluid Path Components	1.010
b. Non-Fluid Path Components	1.011
C. Manufacturer	1.012
D. Methods of Manufacturing and Packaging	1.013
1. Elution Set Assembly	1.013
2. Column Assembly	1.027
3. Mo-99 Concentrate Preparation	1.040
4. Generator Production	1.058
5. Generator Sizes and Production Scenario	1.078
6. Eluant Manufacture	1.083
7. Technostat Vial	1.121
8. Evacuated Vials	1.146
9. Accessory Pack	1.186
10. Packing and Shipping	1.205
E. Final Product Specifications	2.001
1. Method Validation Reports	2.013
2. Sampling Requirements	2.154
F. Stability	2.164
1. Introduction and Overview	2.164
2. Generator Eluant (135 mL)	2.165
3. Generator Eluant (10 mL in-house test)	2.178
4. Technostat Vial	2.186
5. Generator Performance (Protocol A)	<u>2.201</u>
6. Tc-99m/Kit Performance (Protocol B)	2.341
7. GMP Stability Protocols	2.370
III. Labeling	2.380
Referenced Documents	3.001
Standard Test Methods (STMs)	4.001
Standard Operating Procedures (SOPs)	5.001
Specifications	

Attachment I  
3 of 6

PHARMACEUTICAL R & D  
PHARMACEUTICS SECTION  
STABILITY PROTOCOL  
PAGE 1 OF 3

Product: Code 100/107H Hybrid Mo-99/Tc-99m Generators Date: 5-May-91  
LOT NO.: Original 26-May-92  
PURPOSE: Comparison of Hybrid and M/H Generator Performance & Pharmaceutical Quality of Sodium Pertechnetate Tc-99m Injection. FORMULATION: As per Code 100/107C Code 100/107H D225 & D228 Batch Sheets  
CONTAINER: Code 100/107H Generator System as Shown in Exploded Drawing on Page 1.005 of Volume 1.  
CLOSURE: Code L378 Stopper 13 mm Column, Punched Code L325 Stopper, Connector Fitting Code K230 & L376 Closure, Aluminum

DATE MANUFACTURED:

DATE STUDY INITIATED:

GENERATOR/Tc-99m		ELUTION/TEST SCHEDULE <sup>2</sup>	
QUALITY TEST	LIMITS	Elution No.	TEST INTERVAL
Tc-99m Yield	>70% of available Tc-99m	1 thru 10	Initial
Radionuclidic Purity:			
Mo-99	<0.15 uCi Mo-99 per mCi of Tc-99m	1 thru 10	Init & 12 Hr
I-131	<0.05 uCi of I-131 per mCi of Tc-99m	1st & 10th	Init & 12 Hr
Ru-103	<0.05 uCi of Ru-103 per mCi of Tc-99m	1st & 10th	Init & 12 Hr
Sr-89	<0.0006 uCi Sr-89 per mCi of Tc-99m	1st & 10th	Init & 12 Hr
Sr-90	<0.00006 uCi Sr-90 per mCi of Tc-99m	1st & 10th	Init & 12 Hr
Other Beta & Gamma	<0.1 uCi Other Beta & Gamma/mCi Tc-99m	1st & 10th	Init & 12 Hr
Gross Alpha	<0.000001 uCi Alpha per mCi Tc-99m	1st & 10th	Init & 12 Hr

2. All generators to be eluted daily on Monday through Friday up to the expiry date of the generator.

PHARMACEUTICAL R & D  
PHARMACEUTICS SECTION  
STABILITY PROTOCOL  
PAGE 2 OF 3

PRODUCT: Code 100/107H Hybrid Mo-99/Tc99m  
Generators

Date: 5-May-91

Original 26-May-92

GENERATOR/TC-99M		ELUTION/TEST SCHEDULE	
QUALITY TEST	LIMITS	Elution No.	Test Interval
Radionuclidic Identity	140 Kev gamma	1st & 10th	Init & 12 Hr
Radiochemical Purity	>95% as $\text{TcO}_4^-$	1, 5 & 10th	Init & 12 Hr
Appearance	Clear, Colorless, Free of Visible Particulates.	1, 5 & 10th	Init & 12 Hr
pH	4.5 to 7.5	1, 5 & 10th	Init & 12 Hr
Aluminum	<10 ug/ml	1, 5 & 10th	Init
NaCl	0.8 to 1.0%	1st & 10th	Init
Endotoxin	<175 Eu/elution	1st & 10th	Init
Sterility	Conforms	1st & 10th	Init & 12 Hr

PHARMACEUTICAL R & D  
PHARMACEUTICS SECTION  
STABILITY PROTOCOL  
Page 3 of 3

PRODUCT: Code 100/107H Hybrid Mo-99/Tc99m  
Generators (Cont'd)

Date: 5-May-91

Original 26-May-92

Generator Allocation<sup>3</sup> Chart

Generator		Storage Conditions <sup>4</sup>		
Type	Size	Refrig.	RT	50°C
M/H	0.25 Ci	X	X	X
Hybrid	0.25 Ci	X	X	X
M/H	1.5 Ci	X	X	X
Hybrid	1.5 Ci	X	X	X
M/H	3.0 Ci	X	X	X
Hybrid	3.0 Ci	X	X	X
M/H	25.0 Ci	X	X	X
Hybrid	25.0 Ci	X	X	X

Formulator \_\_\_\_\_

Supervisor \_\_\_\_\_

- A minimum of 3 lots of generators will be manufactured and tested. Each lot will consist of an equal number of M/H (Control) generators and Hybrid Generators.
- Generators are to be placed at designated storage conditions after packaging into shipping cartons. The generators will be unpacked and transferred to room temperature storage just before the first elution.

Attachment I  
6 of 6

Mallinckrodt Medical, St. Louis, Missouri

TABLE A-X2005-1. HYBRID Tc-99m GENERATOR. (Per Cent Yield of Tc-99m from Generator)

TEST CATEGORY

Technetium-99m Yield (% Elution Efficiency)  
(Limit = > 70%)

Generator Lot No. X2005  
Date Manufactured 03/13/92  
Date Testing Initiated 03/16/92

Type Gen.	Gen. Size	Gen. No.	1 Mon.	2 Tues.	3 Wed.	4 Thur.	5 Fri.	6 Mon.	7 Tues.	8 Wed.	9 Thur.	10 Fri.
2-8C:	(Cl)											
CONTROL	25.0	4	108.23	94.10	91.09	92.75	94.22	93.40	93.17	93.43	92.91	93.49
HYBRID	25.0	1	108.13	96.64	91.36	92.57	95.81	94.12	93.51	93.05	91.76	94.49
15-30C:												
CONTROL	25.0	5	104.09	93.55	91.40	92.37	93.72	92.90	93.17	92.54	92.86	93.35
HYBRID	25.0	2	107.64	97.03	94.87	95.99	98.02	97.32	97.12	96.12	96.11	96.59
50C:												
CONTROL	25.0	6	99.27	92.73	91.00	92.17	93.46	92.90	93.17	92.54	92.39	92.76
HYBRID	25.0	3	103.60	92.12	90.01	91.40	92.93	93.86	91.76	92.00	92.88	91.74

TRADE SECRET

JULY 1992

2.293